CD24 and triple-negative breast carcinoma: For example, Barkal et al. (61) reported that CD24 signaling through macrophage Siglec-10 is a potential therapeutic target for cancer immunotherapy (Figure 2), as blockade of CD24-Siglec-10 signaling can promote macrophage phagocytosis of triple-negative breast cancer and ovarian cancer cells (61).